RecruitingNot ApplicableNCT05562960

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Sponsor

National Taiwan University Hospital

Enrollment

20 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Amyotrophic Lateral Sclerosis Plasmapheresis

Summary

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Plasmapheresis for people with amyotrophic lateral sclerosis and plasmapheresis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.